These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 11334057

  • 1. Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humans.
    De Boer RH, Roskos LK, Cheung E, Fox S, Basser RL, Marty J, Begley CG, Cebon J.
    Growth Factors; 2000; 18(3):215-26. PubMed ID: 11334057
    [Abstract] [Full Text] [Related]

  • 2. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
    Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Byrne J, Menchaca DM, Fox RM, Begley CG.
    Blood; 1997 May 01; 89(9):3118-28. PubMed ID: 9129014
    [Abstract] [Full Text] [Related]

  • 3. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
    Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB.
    Blood; 1996 Jul 15; 88(2):511-21. PubMed ID: 8695799
    [Abstract] [Full Text] [Related]

  • 4. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
    Shibuya K, Akahori H, Takahashi K, Tahara E, Kato T, Miyazaki H.
    Blood; 1998 Jan 01; 91(1):37-45. PubMed ID: 9414267
    [Abstract] [Full Text] [Related]

  • 5. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
    Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Hussein S, Alt C, Menchaca D, Tomita D, Marty J, Fox RM, Begley CG.
    Lancet; 1996 Nov 09; 348(9037):1279-81. PubMed ID: 8909381
    [Abstract] [Full Text] [Related]

  • 6. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA, Marzec UM, Kelly AB, Cheung E, Tomer A, Nichol JL, Hanson SR, Stead RB.
    Blood; 1997 Jan 01; 89(1):155-65. PubMed ID: 8978288
    [Abstract] [Full Text] [Related]

  • 7. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
    Basser RL.
    Stem Cells; 1998 Jan 01; 16 Suppl 2():225-9. PubMed ID: 11012194
    [Abstract] [Full Text] [Related]

  • 8. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M, Menchaca D, Holden J, Waller EK.
    Exp Hematol; 2002 Sep 01; 30(9):1044-50. PubMed ID: 12225796
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
    Basser RL, Underhill C, Davis I, Green MD, Cebon J, Zalcberg J, MacMillan J, Cohen B, Marty J, Fox RM, Begley CG.
    J Clin Oncol; 2000 Aug 01; 18(15):2852-61. PubMed ID: 10920133
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics, pharmacodynamics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys.
    Sola MC, Christensen RD, Hutson AD, Tarantal AF.
    Pediatr Res; 2000 Feb 01; 47(2):208-14. PubMed ID: 10674348
    [Abstract] [Full Text] [Related]

  • 11. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
    Geissler K, Yin JA, Ganser A, Sanz MA, Szer J, Raghavachar A, Hoelzer D, Martinez C, Taylor K, Kanz L, To LB, Archimbaud E.
    Ann Hematol; 2003 Nov 01; 82(11):677-83. PubMed ID: 14530872
    [Abstract] [Full Text] [Related]

  • 12. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
    Kabaya K, Akahori H, Shibuya K, Nitta Y, Ida M, Kusaka M, Kato T, Miyazaki H.
    Stem Cells; 1996 Nov 01; 14(6):651-60. PubMed ID: 8948023
    [Abstract] [Full Text] [Related]

  • 13. Thrombopoietin therapy increases platelet yields in healthy platelet donors.
    Kuter DJ, Goodnough LT, Romo J, DiPersio J, Peterson R, Tomita D, Sheridan W, McCullough J.
    Blood; 2001 Sep 01; 98(5):1339-45. PubMed ID: 11520780
    [Abstract] [Full Text] [Related]

  • 14. Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia.
    Nakamura M, Toombs CF, Duarte IG, Ronson RS, Schmarkey LS, Katzmark SL, Robinson J, Dillehay DL, Vinten-Johansen J, Guyton RA.
    Ann Thorac Surg; 1998 Oct 01; 66(4):1216-23. PubMed ID: 9800809
    [Abstract] [Full Text] [Related]

  • 15. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
    Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J.
    Bone Marrow Transplant; 2000 Jul 01; 26(2):141-5. PubMed ID: 10918423
    [Abstract] [Full Text] [Related]

  • 16. Overview of the safety and biologic effects of PEG-rHuMGDF in clinical trials.
    Sheridan W, Menchaca D.
    Stem Cells; 1998 Jul 01; 16 Suppl 2():193-8. PubMed ID: 11012191
    [Abstract] [Full Text] [Related]

  • 17. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation.
    O'Malley CJ, Rasko JE, Basser RL, McGrath KM, Cebon J, Grigg AP, Hopkins W, Cohen B, O'Byrne J, Green MD, Fox RM, Berndt MC, Begley CG.
    Blood; 1996 Nov 01; 88(9):3288-98. PubMed ID: 8896392
    [Abstract] [Full Text] [Related]

  • 18. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
    Kabaya K, Shibuya K, Torii Y, Nitta Y, Ida M, Akahori H, Kato T, Kusaka M, Miyazaki H.
    Bone Marrow Transplant; 1996 Dec 01; 18(6):1035-41. PubMed ID: 8971370
    [Abstract] [Full Text] [Related]

  • 19. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients.
    Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK.
    Blood; 1996 Jul 01; 88(1):366-76. PubMed ID: 8704197
    [Abstract] [Full Text] [Related]

  • 20. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
    Farese AM, MacVittie TJ, Roskos L, Stead RB.
    Stem Cells; 2003 Jul 01; 21(1):79-89. PubMed ID: 12529554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.